{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:53:18Z","timestamp":1791280398722,"version":"4.1.0"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_dmpt-2025-0087_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the impact of the TNF-\u03b1 promoter SNP -308G\/A on therapeutic response, serum drug levels, and immunogenicity of TNF inhibitors in chronic inflammatory rheumatic diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2025-0087_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This cross-sectional, multicentric study included 73 patients: 32 with rheumatoid arthritis (RA) and 41 with spondyloarthritis (SpA). Serum drug levels (SDL) and anti-drug antibodies (ADA) were quantified by ELISA (Promonitor\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ). Genotyping for SNP -308 was performed via PCR-RFLP. Therapeutic response was assessed at 6\u00a0months using delta DAS28 and EULAR response in RA and delta Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), BASDAI20 and BASDAI50 responses in SpA patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2025-0087_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In RA, the heterozygous G\/A genotype was significantly associated with a greater reduction in median DAS28 compared to G\/G (p=0.039) and a higher proportion of good EULAR responders (p=0.154). In SpA, G\/A carriers showed larger decreases in BASDAI scores though differences were not statistically significant. Across both diseases, the G\/A genotype was associated with significantly higher median serum drug levels (p=0.032). No association was observed between SNP -308G\/A and ADA positivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2025-0087_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The TNF-\u03b1 -308G\/A polymorphism may be a predictive marker of TNF inhibitor efficacy in RA, potentially influencing serum drug levels while immunogenicity appears unaffected. Larger prospective studies are needed to confirm these findings and explore additional determinants of TNF inhibitor response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/dmpt-2025-0087","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:59:01Z","timestamp":1784797141000},"page":"169-176","source":"Crossref","is-referenced-by-count":0,"title":["Impact of TNF-alpha -308 G\/A polymorphism on response to TNF inhibitors in Tunisian patients with inflammatory rheumatic diseases"],"prefix":"10.1515","volume":"41","author":[{"given":"Ines","family":"Mahmoud","sequence":"first","affiliation":[{"name":"Rheumatology Department , Charles Nicolle Hospital , Tunis , Tunisia"},{"name":"Faculty of Medicine of Tunis , University of Tunis El Manar , Tunis , Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syrine","family":"Zanned","sequence":"additional","affiliation":[{"name":"Rheumatology Department , Charles Nicolle Hospital , Tunis , Tunisia"},{"name":"Faculty of Medicine of Tunis , University of Tunis El Manar , Tunis , Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4623-6284","authenticated-orcid":false,"given":"Leila","family":"Rouached","sequence":"additional","affiliation":[{"name":"Rheumatology Department , Charles Nicolle Hospital , Tunis , Tunisia"},{"name":"Faculty of Medicine of Tunis , University of Tunis El Manar , Tunis , Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Bouden","sequence":"additional","affiliation":[{"name":"Rheumatology Department , Charles Nicolle Hospital , Tunis , Tunisia"},{"name":"Faculty of Medicine of Tunis , University of Tunis El Manar , Tunis , Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-9014","authenticated-orcid":false,"given":"Moalla","family":"Myriam","sequence":"additional","affiliation":[{"name":"Rheumatology Department , Charles Nicolle Hospital , Tunis , Tunisia"},{"name":"Faculty of Medicine of Tunis , University of Tunis El Manar , Tunis , Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwar","family":"Ben Dhia","sequence":"additional","affiliation":[{"name":"Rheumatology Department , Charles Nicolle Hospital , Tunis , Tunisia"},{"name":"Faculty of Medicine of Tunis , University of Tunis El Manar , Tunis , Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawdha","family":"Tekaya","sequence":"additional","affiliation":[{"name":"Rheumatology Department , Charles Nicolle Hospital , Tunis , Tunisia"},{"name":"Faculty of Medicine of Tunis , University of Tunis El Manar , Tunis , Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aicha","family":"Ben Tekaya","sequence":"additional","affiliation":[{"name":"Rheumatology Department , Charles Nicolle Hospital , Tunis , Tunisia"},{"name":"Faculty of Medicine of Tunis , University of Tunis El Manar , Tunis , Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Abdelmoula","sequence":"additional","affiliation":[{"name":"Rheumatology Department , Charles Nicolle Hospital , Tunis , Tunisia"},{"name":"Faculty of Medicine of Tunis , University of Tunis El Manar , Tunis , Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imen","family":"Sfar","sequence":"additional","affiliation":[{"name":"Immunology Department , Charles Nicolle Hospital , Tunis , Tunisia"},{"name":"Faculty of Medicine of Tunis , University of Tunis El Manar , Tunis , Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"2026100609023866260_j_dmpt-2025-0087_ref_001","doi-asserted-by":"crossref","unstructured":"Almutairi, K, Nossent, J, Preen, D, Keen, H, Inderjeeth, C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int 2021;41:863\u201377. https:\/\/doi.org\/10.1007\/s00296-020-04731-0.","DOI":"10.1007\/s00296-020-04731-0"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_002","doi-asserted-by":"crossref","unstructured":"Dean, LE, Jones, GT, MacDonald, AG, Downham, C, Sturrock, RD, Macfarlane, GJ. Global prevalence of ankylosing spondylitis. Rheumatol Oxf Engl 2014;53:650\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/ket387.","DOI":"10.1093\/rheumatology\/ket387"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_003","doi-asserted-by":"crossref","unstructured":"Moelants, EAV, Mortier, A, Van Damme, J, Proost, P. Regulation of TNF-\u03b1 with a focus on rheumatoid arthritis. Immunol Cell Biol 2013;91:393\u2013401. https:\/\/doi.org\/10.1038\/icb.2013.15.","DOI":"10.1038\/icb.2013.15"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_004","doi-asserted-by":"crossref","unstructured":"El-Tahan, RR, Ghoneim, AM, El-Mashad, N. TNF-\u03b1 gene polymorphisms and expression. SpringerPlus 2016;5:1508. https:\/\/doi.org\/10.1186\/s40064-016-3197-y.","DOI":"10.1186\/s40064-016-3197-y"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_016","doi-asserted-by":"crossref","unstructured":"Miler, M, Nikolac Gabaj, N, \u0106elap, I, Grazio, S, Toma\u0161i\u0107, V, Bi\u0161\u0107anin, A, et al.. Association of polymorphisms in promoter region of TNF-\u03b1 -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy. Rheumatol Int 2021;41:2195\u2013203. https:\/\/doi.org\/10.1007\/s00296-021-05016-w.","DOI":"10.1007\/s00296-021-05016-w"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_005","doi-asserted-by":"crossref","unstructured":"Hajeer, AH, Hutchinson, IV. TNF-? gene polymorphism: clinical and biological implications. Microsc Res Tech 2000;50:216\u201328. https:\/\/doi.org\/10.1002\/1097-0029(20000801)50:3<216::aid-jemt5>3.0.co;2-q.","DOI":"10.1002\/1097-0029(20000801)50:3<216::AID-JEMT5>3.0.CO;2-Q"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_006","doi-asserted-by":"crossref","unstructured":"Aguill\u00f3n, JC, Cruzat, A, Cuenca, J, Cuchacovich, M. Tumor necrosis factor alpha genetic polymorphism as a risk factor in disease. Rev Med Chile 2002;130:1043\u201350.","DOI":"10.4067\/S0034-98872002000900013"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_007","doi-asserted-by":"crossref","unstructured":"Pawlik, A, Florczak, M, Ostanek, L, Brzosko, M, Brzosko, I, Szklarz, BG. TNF-alpha -308 promoter polymorphism in patients with rheumatoid arthritis. Scand J Rheumatol 2005;34:22\u20136.","DOI":"10.1080\/03009740510026373"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_008","unstructured":"Khurshid, S, Zeb, A, Bano, S, Rasheed, U, Zammurrad, S, Khan, MS, et al.. Association of tumour necrosis factor-alpha -308 G\/A promoter polymorphism with susceptibility and disease profile of rheumatoid arthritis. J Ayub Med Coll Abbottabad 2020;32:184\u20138."},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_009","doi-asserted-by":"crossref","unstructured":"Song, G, Seo, Y, Kim, J, Choi, S, Ji, J, Lee, Y. Association between TNF-\u03b1 (-308 A\/G, -238 A\/G, -857 C\/T) polymorphisms and responsiveness to TNF-\u03b1 blockers in spondyloarthropathy, psoriasis and Crohn\u2019s disease: a meta-analysis. Pharmacogenomics 2015 Aug;16:1427\u201337. https:\/\/doi.org\/10.2217\/pgs.15.90.","DOI":"10.2217\/pgs.15.90"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_010","doi-asserted-by":"crossref","unstructured":"Mugnier, B, Reviron, D, Darque, A, Balandraud, N, Roudier, C, Roudier, J. Polymorphism at the position -308 of TNF-\u03b1 gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Res Ther 2004;6:72. https:\/\/doi.org\/10.1186\/ar1114.","DOI":"10.1186\/ar1114"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_011","doi-asserted-by":"crossref","unstructured":"Miceli, RC, Comets, E, Verstuyft, C, Tamouza, R, Loiseau, P, Ravaud, P, et al.. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis 2008;67:478\u201384. https:\/\/doi.org\/10.1136\/ard.2007.074104.","DOI":"10.1136\/ard.2007.074104"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_012","doi-asserted-by":"crossref","unstructured":"Balog, A, Klausz, G, G\u00e1l, J, Moln\u00e1r, T, Nagy, F, Ocsovszky, I, et al.. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 2004;71:274\u201380. https:\/\/doi.org\/10.1159\/000080062.","DOI":"10.1159\/000080062"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_013","doi-asserted-by":"crossref","unstructured":"Seitz, M, Wirthmuller, U, Moller, B, Villiger, PM. The -308 tumour necrosis factor- gene polymorphism predicts therapeutic response to TNF -blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology 2007;46:93\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/kel175.","DOI":"10.1093\/rheumatology\/kel175"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_014","doi-asserted-by":"crossref","unstructured":"Chatzikyriakidou, A, Georgiou, I, Voulgari, PV, Venetsanopoulou, AI, Drosos, AA. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients\u2019 response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Rheumatology 2007;46:1034\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/kem041.","DOI":"10.1093\/rheumatology\/kem041"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_015","doi-asserted-by":"crossref","unstructured":"Netz, U, Carter, JV, Eichenberger, MR, Dryden, GW, Pan, J, Rai, SN, et al.. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in crohn\u2019s disease. World J Gastroenterol 2017;23:4958\u201367. https:\/\/doi.org\/10.3748\/wjg.v23.i27.4958.","DOI":"10.3748\/wjg.v23.i27.4958"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_017","doi-asserted-by":"crossref","unstructured":"Fonseca, JE, Carvalho, T, Cruz, M, Nero, P, Sobral, M, Mour\u00e3o, AF, et al.. Polymorphism at position -308 of the tumour necrosis factor gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 2005;64:793\u20134. https:\/\/doi.org\/10.1136\/ard.2004.028167.","DOI":"10.1136\/ard.2004.028167"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_018","doi-asserted-by":"crossref","unstructured":"Kang, CP, Lee, KW, Yoo, DH, Kang, C, Bae, SC. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 2005;44:547\u201352. https:\/\/doi.org\/10.1093\/rheumatology\/keh550.","DOI":"10.1093\/rheumatology\/keh550"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_019","doi-asserted-by":"crossref","unstructured":"Swierkot, J, Bogunia Kubik, K, Nowak, B, Bia\u0142ow\u0105s, K, Korman, L, G\u0119bura, K, et al. FRI0053 analysis of associations between tumor necrosis factor-alpha (TNFA -308 g>a, tnfa -238 g>a, tnfa -857 c>t) and tnf receptors (TNFRA 36 a>g, tnfrb 676 t>g) gene polymorphisms status and responsiveness to tnf-a blockers in rheumatoid arthritis. Ann Rheum Dis. 2013;72:386.","DOI":"10.1136\/annrheumdis-2013-eular.1180"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_020","doi-asserted-by":"crossref","unstructured":"Cui, J, Saevarsdottir, S, Thomson, B, Padyukov, L, Van Der Helm, MM, Nititham, J, et al.. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2010;62:1849\u201361. https:\/\/doi.org\/10.1002\/art.27457.","DOI":"10.1002\/art.27457"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_021","doi-asserted-by":"crossref","unstructured":"Jan\u010di\u0107, I, Arsenovi\u0107 Ranin, N, \u0160efik Bukilica, M, \u017divojinovi\u0107, S, Damjanov, N, Spasovski, V, et al.. 174G\/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. Rheumatol Int 2013;33:1481\u20136. https:\/\/doi.org\/10.1007\/s00296-012-2586-y.","DOI":"10.1007\/s00296-012-2586-y"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_022","doi-asserted-by":"crossref","unstructured":"D\u00e1vila Fajardo, C, M\u00e1rquez, A, Pascual Salcedo, D, Moreno Ramos, MJ, Garc\u00eda Portales, R, Magro Checa, C, et al.. Confirmation of -174G\/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenet Genom 2014;24:1\u20135. https:\/\/doi.org\/10.1097\/FPC.0000000000000013.","DOI":"10.1097\/FPC.0000000000000013"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_023","doi-asserted-by":"crossref","unstructured":"Ongaro, A, Mattei, M, Pellati, A, Caruso, A, Ferretti, S, Masieri, F, et al.. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNF?? Therapy in rheumatoid arthritis? Rheumatol Int 2008;28:901\u20138.","DOI":"10.1007\/s00296-008-0552-5"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_024","doi-asserted-by":"crossref","unstructured":"Swierkot, J, Bogunia Kubik, K, Nowak, B, Bialowas, K, Korman, L, G\u0119bura, K, et al.. Analysis of associations between polymorphisms\u00a0within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. Jt Bone Spine 2015;82:94\u20139. https:\/\/doi.org\/10.1016\/j.jbspin.2014.08.006.","DOI":"10.1016\/j.jbspin.2014.08.006"},{"key":"2026100609023866260_j_dmpt-2025-0087_ref_025","unstructured":"Moalla, M. Polymorphisme des r\u00e9cepteurs Fc-gamma dans la polyarthrite rhumato\u00efde : influence sur l\u2019efficacit\u00e9 des bioth\u00e9rapies [th\u00e8se : m\u00e9decine]. Tunis: Universit\u00e9 de Tunis El Manar; 2021."}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2025-0087\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2025-0087\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:15:18Z","timestamp":1791278118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2025-0087\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,8,25]]},"published-print":{"date-parts":[[2026,10,6]]}},"alternative-id":["10.1515\/dmpt-2025-0087"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2025-0087","relation":{},"ISSN":["2363-8915"],"issn-type":[{"value":"2363-8915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}